Safety, tolerability, pharmacokinetics and neutrophil elastase inhibitory effects of Sivelestat: A randomized, double-blind, placebo-controlled single- and multiple-dose escalation study in Chinese healthy subjects

CONCLUSION: Sivelestat was safe and well tolerated with appropriate pharmacokinetic parameters, which provided support for more diverse dosing regimen in clinical application.CLINICAL TRIAL REGISTRATION: www.chinadrugtrials.org.cn identifier is CTR20210072.PMID:38336251 | DOI:10.1016/j.ejps.2024.106723

Source: European Journal of Pharmaceutical Sciences - February 9, 2024 Category: Drugs & Pharmacology Authors: Kun Li Lingfang Dong Shan Gao Jingying Zhang Yinghua Feng Li Gu Jie Yang Xing Liu Yaqin Wang Zhenkun Mao Dandan Jiang Zhengchao Xia Guoliang Zhang Jingwen Tang Peizhi Ma Wei Zhang Source Type: research